INNATE PHARMA SA (IPHA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IPHA POWR Grades
- IPHA scores best on the Sentiment dimension, with a Sentiment rank ahead of 78.85% of US stocks.
- The strongest trend for IPHA is in Quality, which has been heading down over the past 69 days.
- IPHA's current lowest rank is in the Momentum metric (where it is better than 4.13% of US stocks).
IPHA Stock Summary
- Innate Pharma SA's stock had its IPO on October 18, 2019, making it an older stock than merely 6.71% of US equities in our set.
- With a year-over-year growth in debt of 117.09%, Innate Pharma SA's debt growth rate surpasses 91.07% of about US stocks.
- Revenue growth over the past 12 months for Innate Pharma SA comes in at -67.83%, a number that bests only 2.1% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are PZG, SONN, INFI, NVEC, and PULM.
- IPHA's SEC filings can be seen here. And to visit Innate Pharma SA's official web site, go to www.innate-pharma.com.
IPHA Stock Price Chart Interactive Chart >
IPHA Price/Volume Stats
| Current price | $2.91 | 52-week high | $11.95 |
| Prev. close | $2.91 | 52-week low | $2.66 |
| Day low | $2.89 | Volume | 28,400 |
| Day high | $3.03 | Avg. volume | 25,267 |
| 50-day MA | $3.08 | Dividend yield | N/A |
| 200-day MA | $4.33 | Market Cap | 232.01M |
INNATE PHARMA SA (IPHA) Company Bio
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.
Latest IPHA News From Around the Web
Below are the latest news stories about Innate Pharma SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022MARSEILLE, France, February 15, 2022--Number of shares and voting rights of Innate Pharma as of February 1, 2022 |
Innate Pharma to Participate in Upcoming Investor ConferencesMARSEILLE, France, February 04, 2022--Innate Pharma to participate in upcoming investor conferences |
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022MARSEILLE, France, January 24, 2022--Number of shares and voting rights of Innate Pharma as of January 1, 2022 |
Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed LoansMARSEILLE, France, January 05, 2022--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans |
Innate Pharma (NASDAQ:IPHA) Stock Rating Upgraded by Zacks Investment ResearchZacks Investment Research upgraded shares of Innate Pharma (NASDAQ:IPHA) from a sell rating to a hold rating in a report published on Thursday morning, Zacks.com reports. According to Zacks, Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The companys commercial-stage product includes [] |
IPHA Price Returns
| 1-mo | 3.56% |
| 3-mo | -14.41% |
| 6-mo | -39.38% |
| 1-year | -24.41% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -36.18% |
| 2021 | 11.49% |
| 2020 | -36.49% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...